Health Care · Pharmaceutical Preparations

BBOT BridgeBio Oncology Therapeutics Inc SEC Filings & Insider Trading Activity 2026

company
CIK 186910553 filings

BBOT at a glance

BridgeBio Oncology Therapeutics Inc (BBOT, SEC CIK 1869105) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Oncology Therapeutics Inc (BBOT) reported revenue of $11.3 million (up 77.9% from FY2024) and a net loss of $134.0 million. Diluted EPS was -$4.30.
  • As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding BridgeBio Oncology Therapeutics Inc (BBOT) shares worth $54.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Beltran Pedro on November 18, 2026 of 1,870 shares at $1.84 per share.
  • In the last 90 days, BBOT insiders reported 0 open-market purchases ($0) and 2 open-market sales ($4K) on Form 4, a net sale of $4K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$11.3M
+77.9% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$4K
13F holders
16 funds
$54.8M · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • No product revenue in Q3 2026 or Q3 2025, reflecting clinical-stage status
  • Operating margin not applicable, operating loss $37.5M vs $49.2M YoY
  • R&D strongest focus: $29.6M, down 16% YoY; trial and consumables expenses $20.1M
  • Cash, equivalents and marketable securities $315.3M at September 30, 2026, expected to fund at least twelve months
  • Operating cash outflow $108.6M vs $71.7M YoY; $500.0M shelf and $200.0M ATM established, with no ATM sales by quarter-end

Risk Factors

  • Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 could restrict Chinese sole-source suppliers
  • Most material regulatory update: FDA leadership changes and post-July 2024 Supreme Court ruling increase approval uncertainty
  • Clinical risk: Phase 1 trials for BBO-8520, BBO-10203 and BBO-11818 may fail to demonstrate safety or efficacy
  • Competitive risk: Two FDA-approved KRASG12C inhibitors compete directly with BBO-8520
  • Liquidity risk: Existing cash, cash equivalents and marketable securities expected to fund operations into 2029, not regulatory approval of candidates

AI summary of the BBOT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces BBOT financial results for quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly results and management commentary

Item EX-99.1: Item EX-99.1

  • BBO-8520 plus pembrolizumab achieved 75% ORR at 500 mg QD and 53% across doses in 2L+ KRAS G12C inhibitor-experienced NSCLC
  • BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 inhibitor-naïve NSCLC patients, supporting differentiated efficacy potential
Filed Nov 5, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Medical and Development Officer Yong Ben, M.D., M.B.A. resigning effective January 8, 2027
  • Departure not related to disagreements over company operations, policies, or practices
Filed Sep 8, 2026Full analysis →

Item 8.01: Other Events

  • September 8, 2026 press release highlights new BBO-8520 data and strategic focus on 2L+ NSCLC combinations
  • Pipeline emphasis includes BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers

Item EX-99.1: Item EX-99.1

  • BBO-8520 plus pembrolizumab produced 75% ORR at 500 mg QD in 2L+ NSCLC after prior KRAS G12C inhibitor treatment
  • BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 previously untreated 2L+ NSCLC patients

Item EX-99.2: Item EX-99.2

  • BBOT prioritizing BBO-8520 plus pembrolizumab in post-G12C NSCLC, while deprioritizing 1L NSCLC development and further BBO-8520 investment there
  • BBO-8520 combination delivered 75% ORR at 500 mg QD and 53% across doses in 17 G12C inhibitor experienced patients

AI summaries of BBOT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BBOT

Don't miss the next BBOT filing

  • Alerts as it files. A push when BBOT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BBOT, by share count.
  • Ask anything. An AI agent that reads every BBOT filing and answers with sources.

BBOT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Beltran PedroSellNov 18, 2026$1.84
Cobo MarcSellNov 13, 2026$2.37
Cobo MarcFOct 21, 2026$2.68
Elmelech IdanFOct 1, 2026$3.94
Beltran PedroFOct 1, 2026$3.94
Ben YongFOct 1, 2026$3.94
Cobo MarcFOct 1, 2026$3.94
Cobo MarcFSep 10, 2026$5.52

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$6.4M$11.3M
Operating Income-$42K-$584K-$145.8M
Net Income-$42K$7.6M-$134.0M
Op. Margin--9.2%-1285.5%
Net Margin-119.2%-1181.7%
Balance Sheet
Total Assets$333K$194.4M$448.4M
Equity-$64K-$3.7M$411.1M
ROE65.6%-203.6%-32.6%
Per Share
EPS-$-5756.41$-4.30
Cash Flow
Operating CF--$764K-$113.9M
CapEx-$49K$606K

Source: XBRL data in BridgeBio Oncology Therapeutics Inc (BBOT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BBOT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BBOT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202616$54.8M
Q2 202616$89.6M
Q1 202613$85.6M
Q4 202514$124.9M
Q3 202511$112.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 70 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BBOT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 17, 2026--
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 23, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Sep 14, 2026--
8-KSep 8, 2026Analysis-
8-KAug 11, 2026Analysis-
10-QAug 11, 2026-
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 6, 2026--
8-KJun 22, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--

Related Health Care companies

All Health Care →

BBOT SEC filings: frequently asked questions

Are BBOT insiders buying or selling?

In the last 90 days, BridgeBio Oncology Therapeutics Inc (BBOT) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $3,628 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BBOT stock?

As of September 30, 2026, the largest BridgeBio Oncology Therapeutics Inc (BBOT) holders among the 13F filers tracked by SignalX were BlackRock ($16.4 million), Alphabet Inc ($11.6 million), Citadel Advisors LLC ($11.1 million), Vanguard Capital Management LLC ($8.2 million), State Street Corp ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BBOT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Oncology Therapeutics Inc (BBOT) reported revenue of $11.3 million (up 77.9% from FY2024) and a net loss of $134.0 million. Diluted EPS was -$4.30. The figures come from the XBRL data in the 10-K.

What did BBOT report in its latest 8-K?

BridgeBio Oncology Therapeutics Inc (BBOT) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces BBOT financial results for quarter ended September 30, 2026.

What are the latest BBOT SEC filings?

BridgeBio Oncology Therapeutics Inc (BBOT) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 20, 2026.

What is BBOT's SEC CIK number?

BridgeBio Oncology Therapeutics Inc (BBOT)'s SEC Central Index Key (CIK) is 1869105. EDGAR lists every BBOT filing under that number.

Ask anything about BBOT

The research agent reads BBOT's filings, financials, insider trades and 13F holders, then answers with sources.